Becton Dickinson
30-Second Executive Brief
Executive Assessment
Becton Dickinson functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A global medical technology company that completed the spin-off of its former Biosciences and Diagnostic Solutions business (combined with Waters Corporation) on February 9, 2026, sharpening its focus on core medical and interventional segments. BD reported Q3 fiscal 2026 revenue of $4.98 billion (beating estimates) and raised its adjusted EPS guidance, while announcing a strategic partnership with Wellstar Health System to integrate its Pyxis Pro dispensing and Alaris infusion technologies with AI through BD Incada.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Defense — $50,322: DELIVERIES OF MICROBIOLOGICAL/BACTERIOLOGICAL CULTURES FOR GOVERNMENT-OWNED BD MAX SYSTEM AND MEDICAL SUPPLIES FOR THE U.S. ARMY HEALTH CENTER VICENZA, ITALY.
USAspending.gov · Oct 1, 2025
Department of Defense — $43,227: MICROBIOLOGY MEDIA PLATES
USAspending.gov · Oct 1, 2024
Department of Defense — $43,171: BD MAX - FULL RISK MAINTENANCE SERVICES
USAspending.gov · Jun 1, 2022
Department of State — $16,248: LR26017_IMMUNOLOGY BD FLOWCYTOMETRY SYSTEM REAGENTS
USAspending.gov · Apr 14, 2026
Department of Defense — $15,675: BECTON DICKINSON BD MAX CONSUMABLES
USAspending.gov · Mar 1, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Becton, Dickinson and Company — BD reports third quarter fiscal 2026 financial resultscompany
- BD Newsroom — BD completes spin-off of Biosciences and Diagnostic Solutions businesscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Becton Dickinson — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
The Waters spin-off is a bet that a leaner, more focused BD outgrows the combined entity
31% confidenceBD shed its Biosciences and Diagnostic Solutions business to Waters Corporation in February 2026 and immediately posted a Q3 fiscal 2026 revenue beat with raised guidance, while pursuing AI-enabled connected-care partnerships like BD Incada.
This is InsightNodes' own interpretive read: portfolio simplification carries near-term execution risk (new leadership, reduced diversification) but the immediate post-spin-off earnings beat suggests the remaining medical/interventional core is executing well on its own, and BD Incada signals management is using the sharper focus to invest in AI-enabled differentiation within its core segments rather than spreading resources across a broader, less-focused portfolio.
InsightNodes analysis of BD's 2026 portfolio strategy · Aug 14, 2026
Becton Dickinson's Timeline
A sourced, dated history of Becton Dickinson's key moments — founding to present.
Feb 2026 · Spins off Biosciences and Diagnostic Solutions to Waters
BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and combined it with Waters Corporation, sharpening BD's focus on core medical and interventional segments.
Aug 2026 · Q3 FY2026: revenue beats, raises guidance
BD reported Q3 fiscal 2026 revenue of $4.98 billion (beating the $4.89 billion forecast) with EPS of $3.23, and raised its 2026 adjusted EPS guidance following growth across core medical and interventional segments.